ArticleFrontiers in oncology2025
Long-term survival following multimodal therapy for lung cancer with hepatic metastasis: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The liver serves as a predominant metastatic site in advanced lung cancer, with patients developing hepatic metastases demonstrating particularly dismal prognosis and a median survival of approximately 5 months. Currently, no consensus has been established regarding optimal therapeutic strategies for lung cancer with liver metastases. Case presentation: A patient with advanced lung cancer and oligometastatic liver metastases achieved significant tumor regression in both pulmonary and hepatic lesions following combined immunotherapy and chemotherapy. Subsequent radiofrequency ablation was performed for the liver metastasis, while surgical resection of the primary lung lesion resulted in pathological complete response (pCR). The patient has maintained long-term survival without evidence of disease recurrence. Conclusions: For patients with advanced lung cancer and oligometastatic liver metastases demonstrating favorable response to combined immunotherapy and chemotherapy, consolidative surgical resection with adjunctive liver-directed local therapy may be considered, potentially conferring long-term survival benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.